Die Welt
중도 성향
기타
Eine neue Therapie erreicht erstmals „funktionelle Heilung“ chronischer Hepatitis B
Erstmals zeigt eine Studie, dass eine chronische Hepatitis B funktionell geheilt werden kann. Davon profitiert jedoch nur ein Teil der Betroffenen.
"HEPATITIS" · 총 8건
필터 보기현재 지수
50.3
0 = 부정 우세
50 = 중립
100 = 긍정 우세
최근 7일 기준 81,852건을 분석한 결과, 뉴스 심리지수는 50.2(균형)입니다. 긍정 4,012건(4.9%)·중립 75,904건(92.7%)·부정 1,936건(2.4%)이며, 중립 비중이 뚜렷하게 높습니다. 성향 지수는 종합 14.7(중도 균형)입니다.
Erstmals zeigt eine Studie, dass eine chronische Hepatitis B funktionell geheilt werden kann. Davon profitiert jedoch nur ein Teil der Betroffenen.
Erstmals zeigen zwei große Studien, dass eine chronische Hepatitis B funktionell geheilt werden kann. Davon profitiert nur ein Teil der Betroffenen - warum Experten trotzdem auf eine Zulassung hoffen.
Measles in the US, a cholera outbreak in the DRC, TB patient registration drops in Cambodia, Kenya, and Mozambique and closer to home, HIV outbreaks in children have all been linked to what doctors have warned are cuts to programmes and disastrous policy changes. Global funding has shrunk for healthcare across countries that need it the most which is why experts in Pakistan are really getting worried. The effects are immediately clear on the ground. In the busy streets of Lyari, Karachi, Amna Sualeh once navigated confidently through her community as a health worker with the Greenstar Social Marketing’s Sitara Baji (star sister) programme. Women trusted her to provide affordable intrauterine devices (IUDs), counselling on how to space out their children, and basic reproductive health services. “Before, with donor support, we could perform IUD insertions for just Rs500,” she says. “Now it costs up to Rs10,000 in private clinics. Many simply can’t afford it anymore.” Her clients, mostly working-class mothers, have begun skipping visits or turning to unsafe alternatives. As Pakistan’s macroeconomic crisis stretches out, many women have stopped coming altogether as their incomes have shrunk. This refrain is repeated across the provinces as overseas development assistance, once an indispensable backbone of the country’s public health system, contracts sharply. While not a principal focus of the global conversation on the impact of the Great Aid Recession, Pakistan enters the second quarter of the 21st century with its health system already stretched thin. It spends just 0.9 per cent of its GDP on public health, far below the WHO’s 5pc benchmark for universal health coverage. Life expectancy is 67.3 years, which is four years below the South Asian average, and conversely, infant and maternal mortality remain stubbornly high at 50.1 deaths per 1,000 live births and 155 deaths per 100,000 live births, respectively, more than double the rates of neighbours such as Bangladesh and Nepal. These outcomes reflect chronic underinvestment, rigid budgetary structures, and a system that has long relied on overseas technical and financial assistance for crucial health functions that domestic resources have not historically covered. For years, overseas development assistance, including both on-budget funds that flowed through government budgets and off-budget funds directed to NGOs, helped bridge key gaps in the system. While it comprised only a small proportion (around 1pc) of public health spending, much of this assistance was for crucial system functions that have historically been underserved in government budgets and policy. This is particularly true for funding from Global Health Initiatives (GHIs), specialised international financing mechanisms that support priority health programmes around the world, through organisations such as the Global Fund for TB, AIDS and Malaria and Gavi. In Pakistan, this support included the less visible aspects of health, such as supply chain logistics, cold chain management and storage, commodity procurement, monitoring support, and technical capacity building across key programmes like mother and child health, family planning, immunisation, HIV-AIDS, malaria and TB. As laid out in a recent report by think tank Tabadlab, the unprecedented global aid retrenchment crisis that has enveloped the world since 2025 has hit many of these programmes hard. USAID’s suspension led to the closure of over 60 UNFPA-run health facilities in Khyber Pakhtunkhwa, directly disrupting care for 1.7 million people and halting HIV-AIDS programmes in Sindh that were providing life-saving medications to patients. Screengrab from Tabadlab research paper on aid cuts. This was followed by reductions in financial commitments in Pakistan from multilateral GHI donors such as Gavi and The Global Fund, as finances were redistributed across regions and priorities. Drawdowns in Gavi affected vaccination programmes caused layoffs of over 200 vaccinators in Lahore alone. A $27.2 million Global Fund reduction halved TB support in multiple provinces, cut diagnostic kit financing by 75pc, and placed treatment for over 42,000 HIV-positive patients at risk. Across the board, these cuts are eroding important nodes of the health system for which ODA had earlier provided the systemic architecture and connective tissue. Preventative healthcare’s invisible erosion Preventative health programmes—long under-prioritised in domestic health budgets and rarely accorded priority by local politicians and policymakers who tend to focus resources on visible infrastructure—have been disproportionately impacted. Organisations like the Global Fund helped develop monitoring and surveillance systems and trained thousands of frontline workers to prevent and monitor the spread of communicable diseases. Over the past year, many of these programs have been terminated. Dr Ilyas Gondal, former director general of health in Punjab, oversaw the administration of these programmes firsthand. “Preventative healthcare has not been given its due importance here,” he observes. “Donors filled critical gaps in programmes such as the Expanded Programme for Immunisation (EPI), AIDS, Hepatitis and TB through support for training, outreach, health awareness, literature, and logistics. Now, most of that work has stopped across all of these programmes.” Dr Gondal fears that progress on coverage for vaccine-preventable diseases could be reversed if no arrangements are made for alternative financing. Ejaz Mahmood, a community health worker at Indus Hospital in Faisalabad, worked with the Global Fund-supported Infection Prevention and Control (IPC) programme, which trained 10,000 frontline workers in standard operating procedures for infection prevention across the country and developed IPC committees following the Covid-19 pandemic. He describes how most of those IPC committees have now become non-functional, and critical infection prevention training has been abandoned. “No one is there to train health workers anymore. We are already seeing needle-stick injuries rising, with over 111 such cases in Faisalabad this year, along with rising cases of HIV-AIDS and Hepatitis B.” Screengrab from Tabadlab research paper on ODA cuts on Pakistan’s health system. Some of the fallout of such crucial programmes being abandoned may already be contributing to disease outbreaks. Over the past year, Pakistan has witnessed one of the fastest-growing HIV epidemics in the WHO Eastern Mediterranean region, with a 200pc rise in infections between 2010 and 2024. Recent media investigations in Punjab and Sindh uncovered multiple HIV outbreaks originating from health facilities that disproportionately affected children, with the reuse of syringes, non-screening of blood samples, and other unsafe medical and waste management practices identified as the causes. As donors that were crucial in enabling preventative interventions and programmes draw down support, the risk of such outbreaks is likely to increase, unless the funding and institutional structures for these programmes are sustained or replaced with domestic capacity and resources. Tuberculosis detection and treatment in jeopardy Pakistan ranks fifth globally in TB burden, with nearly 650,000 cases and 70,000 deaths annually; over half of cases go undetected. Provincial TB control programmes have long depended on donors for the bulk of programme funding. While provincial governments contribute brick-and-mortar infrastructure for these projects, organisations like The Global Fund financed everything from service delivery to detection and surveillance to commodity stocks. Dr Sher Afghan, director of the TB Control Programme in Balochistan, is direct about the scale of the crisis: “We currently face an 80pc funding gap.” The cuts resulted in a 50pc reduction in programme human resources. “We have had to halve monitoring and surveillance staff, postpone prevalence surveys, and capacity building programmes that were training 800 workers a year.” In resource-strapped provinces with unique geographical access challenges like Balochistan, this has made TB detection increasingly difficult. Programme administrators like Dr Afghan are concerned about the increased risk of undetected transmission. “Every TB-positive patient who is not treated spreads the disease to 12 people on average. Thus, every undiagnosed case means potentially 13 undiagnosed cases.” The Global Fund cut has also triggered a 50pc reduction in district-level monitoring and community interventions staff in Punjab and Khyber Pakhtunkhwa, alongside a 75pc cut in diagnostic testing kits and the elimination of capacity-building. Utilisation of USAID in Pakistan’s healthcare system Life and healthcare programmes; primary healthcare in erstwhile FATA and frontier regions; childhood and neonatal support; malaria control. Screengrab from PIDE research paper on foreign aid, donors and consultants. Babar Shigri, former programme management specialist with USAID Pakistan, observed the impact of donor withdrawal firsthand. In Khyber Pakhtunkhwa and Sindh, USAID supported TB programmes with contact tracing, pharmaceutical products, community mobilisation and management information systems that improved detection rates. “It’s not about funding alone,” he says. “When USAID left, work slowed down overall as one of the main actors driving and coordinating advocacy was gone.” In Balochistan, Dr Sher Afghan is cautiously optimistic that the government will step up to the challenge and is working on creating budgetary space for the programme. But with the sudden shock to a system long dependent on donor-led systems, there is a risk of systemic collapse to the programme unless there is rapid action to create fiscal and institutional mechanisms for transitional planning. Family planning being priced out of access Family planning programmes have been among the hardest hit. Through off-budget ODA, donors like USAID supported access by underwriting everything from supply chains to capacity building for large non-governmental family planning providers such as Greenstar Social Marketing and Rahnuma FPAP. When funding evaporated, the effects were immediate. Dr Syed Azizur Rab, CEO of Greenstar Social Marketing Pakistan, describes a donor-supported network that enabled underserved rural and working-class communities to access contraceptives and SRH services nationwide. “Donor support covered functions ranging from commodity subsidies, training, and logistics to community outreach and monitoring,” he explains. With that support gone, clinics have had to raise fees to cover costs and scaled back services. Screengrab from PIDE research paper on foreign aid, donors and consultants. Access to contraceptives, particularly long-acting ones like IUCDs and implants has been severely affected. According to Dr Rab, due to a lack of domestic production and rising costs of imports, “without donor subsidies, implants and IUCDs in private are simply commercially non-viable.” This effect has been compounded by increased taxes on contraceptives by the government as a revenue measure, further pricing them out of reach amid a prolonged inflationary crisis. Greenstar-affiliated clinicians such as Amna Sualeh now watch clients weigh the increased cost of an IUCD against tighter household budgets. Many are now forgoing modern contraceptive methods altogether and having unintended pregnancies as a result. In Mardan, Khyber Pakhtunkhwa, Noreen Nasir, a lady health visitor and midwife with over two decades of experience, worked for years as a family planning provider with USAID’s now-terminated Building Healthier Families programme. The project supported training and diagnostics, IUCDs, injections and implants for women in working-class neighbourhoods. “We used to be able to provide these commodities and services at a very minimal cost because of donor support,” she says. “Now we have to charge for them and face frequent shortages of implants and injections. At times, I pay for delivery kits out of my own pocket because the client can’t afford them and the delivery would be riskier otherwise.” As a result of the loss of support, she says, increasing numbers of women are turning to unqualified providers and stocks of key family planning products have fallen short. According to Noreen, the loss of access to affordable natal and post-natal care is also affecting infant nutrition, with reduced breastfeeding rates and rising underweight deliveries in the community she serves. Rahnuma FPAP, one of the country’s largest reproductive health networks, has closed dozens of centres. District Programme Manager Farrukh Bashir is pessimistic in his assessment: “When the funding stopped, all project beneficiaries lost access, and we had to close all donor-supported clinics. In facilities where we used to have three doctors, we now have just one. Doctor-client ratios have worsened across the board, and thousands of women from working-class communities have lost reliable sexual and reproductive health care.” Mother and child health fragile gains at risk The cuts have also severely impacted mother and child health programs and services in a country that has long had some of the worst maternal, neonatal and child health outcomes in Asia. Donor financing for these programmes was critical in reducing maternal mortality across the country (from 276 per 100,000 births in 2006 to 155 by 2024). ODA for it was particularly important for remote and marginalised regions of provinces such as Balochistan, where access to facility-based maternal and child healthcare is limited amid resource and geographical access challenges. Community health worker Shazia Ahmad worked with the EU-ECHO project, which helped upgrade basic health units and hospitals in underserved districts, and provided delivery kits, folic acid, nutrition advice, breastfeeding support and health awareness sessions. “The project was very well received in the communities, and we registered over 100,000 women. We were conducting health screenings for mothers and children while also providing nutrition supplements in districts with the highest malnutrition rates in the country.” Screengrab from PIDE research paper on foreign aid, donors and consultants. But with the termination of the project, medicines and services have been halved, and more layoffs are planned. Shazia worries about reversing the substantive gains they had made in rural communities in Balochistan. “The project was very popular with communities, and we were already seeing genuine behavioural change. Now all that work is at risk, and we are unable to follow up on the healthcare needs we had identified.” In a Rahnuma clinic in a working-class neighbourhood in Faisalabad, Punjab, Dr Amna Ehsan once operated under a “no refusal” policy with low charges for marginalised women. Donor funds allowed subsidised medicines and gynaecological OPD services. Now services are being privatised, and fees are rising. “We had very low charges and could provide low-cost medicines which were affordable for the marginalised communities we work in,” she says. Patient volumes, faced with increased fees for services and medicines, have slowed to a trickle. Systemic vulnerabilities and the transition challenge These individual stories of the struggles of health workers and administrators in the face of ODA cuts illustrate the broader structural problems documented in recent analyses of Pakistan’s health system and financing. As is clear, the impact is not just fiscal but functional. ODA, particularly off-budget flows through Global Health Initiatives, were critical for crucial health system functions that public budgets cover only partially or not at all. Bilateral cuts such as the USAID suspension have produced “cliff-edge” disruptions—abrupt programme discontinuities without transitional periods or buffers. Multilateral financing reductions have eroded the infrastructure of vertical disease programmes, including for commodities, diagnostics, surveillance and field operations. Commodity supply chains are particularly vulnerable. Donors handled pooled procurement that secured steep discounts on vaccines, TB drugs and diagnostics. As things stand, domestic systems lack the fiscal flexibility, technical capacity and regulatory agility to absorb these functions quickly. Further, technical assistance withdrawal is eroding surveillance, monitoring, data systems and planning capacity. The result is not total collapse or catastrophe but precise ruptures: stockouts, shortages, laid-off outreach workers, broken referral chains and rising exposure to out-of-pocket costs that can push families deeper into poverty and raise the underappreciated risk of disease outbreaks. While the risks are very real, the current moment also presents an opportunity for the kind of structural change that Pakistan’s health system has long needed. However, the government’s response must move beyond emergency and ad-hoc plugging of gaps and outbreak controls towards transition planning. If governments demonstrate adequate initiative and come together to coordinate, assess and fill these financing gaps, we can secure and build on the fragile health gains of recent years. At Greenstar, Dr Azizur Rab sees this moment as a reform opportunity that could build on what already exists: “The federal and provincial governments will have to look at the models already created with donor money and scale them up. However, this requires government ownership and political will.” If Pakistan seizes the crisis as a catalyst for functional transition—from donor dependence to resilience and sustainability—it can build a fully domestically financed health system capable of protecting the most vulnerable while also preventing outbreaks and creating effective local referral systems and commodity supply chains. The choice, and the cost of inaction, will be measured in lives and in the hard-won public health gains now hanging in the balance.
Countries: Democratic Republic of the Congo, Uganda Source: World Health Organization In response to the current outbreak of Ebola disease caused by Bundibugyo virus occurring in the Democratic Republic of the Congo, with cases also reported in Uganda, WHO convened several of its expert and advisory groups. These groups assessed potential vaccines and therapeutics for both prevention and treatment of Bundibugyo virus disease (BVD). The WHO advisory groups recommended that all the products identified and considered be used exclusively within clinical trials to generate robust data and ensure safe, ethical, and effective research. WHO convened a series of meetings with the WHO R&D Blueprint technical advisory groups on candidate vaccines and therapeutics for BVD. In parallel, WHO also convened the Strategic Advisory Group of Experts on Immunization (SAGE) and its Ebola vaccine working group to advise on the potential role of licensed Ebola vaccines during BVD outbreaks. Key recommendations There are currently no licensed therapeutics or vaccines specifically approved for the prevention and treatment of BVD. Nevertheless, WHO advisory groups considered several candidate products that are promising enough to warrant prioritization for evaluation in clinical trials. WHO is now working closely with the governments of the Democratic Republic of the Congo and Uganda to facilitate the implementation of research evaluation of these products. For treatment of cases: For treatment, the independent experts recommended prioritizing three candidate therapeutics for evaluation in research (i.e. clinical trials) among confirmed BVD cases: the monoclonal antibodies MBP134 and Maftivimab®, as well as the antiviral remdesivir. Combination therapy using a monoclonal antibody and remdesivir is also recommended for evaluation. For prevention of cases: For post-exposure prophylaxis among contacts of confirmed and probable cases, the oral antiviral obeldesivir was determined to be a priority candidate, although experts noted that this approach depends on effective contact tracing, which remains operationally challenging in some of the affected areas of the Democratic Republic of the Congo. Research on post-exposure prophylaxis involves giving tablets of obeldesivir to contacts of cases to evaluate whether this prevents them from developing Ebola disease. The most promising candidate vaccine was determined by the experts to be the single-dose rVSV Bundibugyo vaccine (being developed by the International AIDS Vaccine Initiative or IAVI). The development of this single-dose vaccine candidate will likely require 7–9 months before it is ready to be assessed through a clinical trial for its ability to prevent BDV. Another candidate vaccine, ChAdOx1 Bundibugyo (being developed by Oxford University/Serum Institute of India) could potentially become available within 2–3 months for efficacy assessment through a clinical trial. However, additional animal data are still required to support and confirm further prioritization. Experts noted that a single-dose vaccine approach of this candidate could be suitable for contacts of Ebola cases, whereas a two-dose strategy might be considered for high-risk but unexposed populations such as health-care workers and frontline responders. The convened experts also reviewed the potential role of Ervebo, the only licensed Ebola vaccine. It is approved for use during outbreaks caused by the most common Ebola virus in Africa, from the Orthoebolavirus family. Ervebo is not licensed for prevention of BVD and evidence on cross-protection to other Ebola virus species remains limited and inconclusive. WHO recommends that Ervebo should not be used outside carefully designed research settings, to allow for its performance against BDV to be assessed. Ensuring ethical and safe clinical trials WHO, the governments of the Democratic Republic of the Congo and Uganda, the Africa Centres for Disease Control and Prevention (Africa CDC), the ANRS Emerging infectious diseases (French National Agency for Research on AIDS and Viral Hepatitis), and other scientific partners are working together to develop and implement appropriate protocols to assess the safety and efficacy of the prioritized therapeutics through clinical field trials. WHO calls for accelerated access to essential supplies, stronger community protection, engagement and trust, and coordinated investment in the research, development and evaluation of BVD countermeasures. All research must adhere to the highest ethical standards, under the leadership of the national health authorities and in close consultation with affected communities. In the meantime, our priority is to stop transmission with tools that we have used for decades of Ebola responses, which include disease surveillance, rapid testing and diagnosis, contact tracing, isolation and care for patients, infection prevention and control, community engagement, and safe and dignified burials. Background The WHO R&D Blueprint is a global initiative that allows the rapid activation of research and development activities during epidemics. Its aim is to fast-track the availability of proven effective tests, vaccines, and medicines that can be used to save lives and avert large-scale crises. SAGE is the principal advisory group to WHO for vaccines and immunization. It is charged with advising WHO on overall global policies and strategies, ranging from vaccines and technology, research and development, to delivery of immunization and its linkages with other health interventions. Media Contacts WHO Media Team World Health Organization Email: mediainquiries@who.int
Researchers reported Thursday that in two international studies, about 1 in 5 patients given the experimental drug for six months saw their virus reduced to levels low enough that the immune system could keep it in check.
Most people recover from the infection, but it poses great risks for those who don’t. A new drug may cure 1 in 5 of these patients.
More than 250 million people globally live with chronic hepatitis B.
Country: Sudan Source: UN Children's Fund Please refer to the attached file. Highlights Health services remained a critical lifeline, with over 130,000 women and children accessing primary healthcare services across conflict‑affected areas in March, despite insecurity and access constraints, alongside targeted mobile and integrated outreach in hard‑to‑reach locations to respond to ongoing cholera, measles, dengue and malaria risks. Nutrition needs continued to surge, with 24,500 children admitted for severe acute malnutrition treatment in March and over 825,000 children screened, reflecting expanded outreach and early detection efforts in high‑priority, famine‑risk localities. WASH interventions reached over 650,000 people with access to safe drinking water, helping reduce outbreak risks in overcrowded displacement settings through chlorination activities and rehabilitation of water systems, alongside continued sanitation and hygiene promotion in hotspot areas. Despite these efforts, the 2026 HAC appeal remains critically underfunded, with only 16 per cent of requirements met, severely constraining the scale‑up and continuity of life‑saving services and leaving millions of children at heightened risk. [...] SITUATION OVERVIEW AND HUMANITARIAN NEEDS Sudan continues to face severe humanitarian challenges driven by protracted conflict, shifting frontlines, mass displacement, and recurrent disease outbreaks. As control lines continue to shift across the country’s 18 states, the dynamics of the operating environment remain volatile, with humanitarian needs intensifying in conflict‑affected areas, displacement‑hosting locations, and returnee areas. While the overall internal displacement has decreased to approximately nine million people5 , largely due to voluntary returns, there is persistent and active conflict that continues to displace people in Darfur and Kordofans. Children remain disproportionately affected, accounting for 55 per cent of all internally displaced persons. At the same time, return movements have accelerated, with 3.8 million documented returnees6 , majority (84 per cent) returning from within Sudan and 16 per cent from abroad. Despite the overall reduction in the overall magnitude of displacement, recent hostilities continue to trigger new and localized waves of movements, particularly in Kordofan, Darfur and Blue Nile, regions that have endured decades of protracted conflict. From late October 2025 to March 2026, more than 135,000 people7 were newly displaced across the Kordofan states, while over 13,000 people8 were displaced in Blue Nile State in March alone, primarily from Kurmuk and Geissan localities. With hostilities ongoing, further displacement is expected. Renewed fighting along key routes to Dilling and Kadugli has reintroduced significant access constraints, severely limiting humanitarian reach and the delivery of life-saving assistance to affected populations. Protection risks are escalating as the conflict becomes increasingly characterised by indiscriminate attacks and damage to civilian infrastructure. Shelling and drone strikes continue to result in civilian casualties and the destruction of essential services, including health and education facilities. Recent attacks on El Daein Teaching Hospital in East Darfur9 and on a secondary school and primary healthcare centre in Shukairi village10 , White Nile State, underscore the growing severity of violations against civilian infrastructure and the erosion of safe access to basic services. Food insecurity in Sudan constitutes one of the most severe nutrition crises globally. Recent Integrated Food Security Phase Classification Acute Food Insecurity (IPC-AFI) analyses estimate that over 60 percent of the population (24.6–28.9 million people) are experiencing acute food insecurity (IPC Phase 3+), including more than 6 million in Emergency (IPC Phase 4) and over 750,000 in Catastrophe (IPC Phase 5) with famine conditions confirmed in Al Fasher (North Darfur) and Kadugli (South Kordofan). Famine Early Warning Systems Network (FEWS NET) highlights persistent risk of famine in greater Darfur and Kordofan, particularly in areas experiencing siege-like conditions. An estimated 3.6 million children under five11 are projected to be acutely malnourished in 2026, driven by protracted conflict, displacement, limited access 2 to humanitarian services, and the risk of famine in the most affected areas. The Federal Ministry of Health has declared the end of the cholera outbreak following six consecutive weeks without reported cases—an important milestone. However, public health risks remain high, with multiple disease outbreaks—including measles, diphtheria, dengue, hepatitis E and malaria—continuing to circulate widely. These risks are further exacerbated by overcrowding, poor water and sanitation conditions, and limited access to healthcare, particularly in displacement settings.